Holen Sie sich die Stockscreener-App
2.38
1.24%
-0.03
Schlusskurs vom Vortag:
$2.41
Offen:
$2.4
24-Stunden-Volumen:
19,867
Relative Volume:
0.22
Marktkapitalisierung:
$10.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.88M
KGV:
-3.1733
EPS:
-0.75
Netto-Cashflow:
$-25.20M
1W Leistung:
+3.93%
1M Leistung:
+18.23%
6M Leistung:
-48.05%
1J Leistung:
-65.51%
1-Tages-Spanne:
$2.3527
$2.5107
1-Wochen-Bereich:
$2.29
$2.65
52-Wochen-Spanne:
$1.91
$16.70
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Vergleichen Sie INAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.3749 | 10.94M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.03 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.31 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.04 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.84 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
337.14 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Layoff Tracker: Novo’s Cuts Leave Dozens of Manufacturing Workers Jobless - BioSpace
Bio, semiconductor, content firms to reboot Korea’s IPO market - The Korea Economic Daily Global Edition
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Nuvation Bio: A Rare Gem In The Risky Biotech Space (NYSE:NUVB) - Seeking Alpha
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes - biospace.com
KALA BIO Soars 10.65% on Bullish Analyst Coverage - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Does Gossamer Bio Inc. align with a passive investing strategyJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):